Medscape March 20, 2024
The US Food and Drug Administration (FDA) has approved aprocitentan (Tryvio) to lower blood pressure, in combination with other antihypertensive agents, in adults with treatment-resistant hypertension.
Aprocitentan is the first endothelin receptor antagonist approved for patients with hypertension. The recommended dose is 12.5 mg orally once daily, with or without food.
The efficacy and safety of aprocitentan were demonstrated in the phase 3 PRECISION study of 730 adults with systolic blood pressure ≥ 140 mmHg who were prescribed at least three antihypertensive medications.
Aprocitentan (12.5 mg daily) was well tolerated and statistically superior to placebo in lowering blood pressure at 4 weeks, with a sustained effect at 40 weeks.
Subgroup analyses showed that the blood pressure–lowering effect of aprocitentan...
Today's Sponsors
Today's Sponsor